Baltimore, MD – According to The Baltimore Sun, a groundbreaking study has revealed that GLP-1 drugs, commonly prescribed for diabetes and obesity, hold significant promise in mitigating addiction to various substances. Published on March 4, 2026, by researchers at Washington University in St. Louis, the research examined data from 600,000 veterans diagnosed with type 2 diabetes within the Veterans Affairs health care system over a three-year period.
The findings indicated that patients using GLP-1 medications who had no prior history of substance abuse faced a 14% lower risk of developing addictions to alcohol, tobacco, cannabis, opioids, and cocaine when compared to those not receiving the treatment. The most substantial risk reduction, at 25%, was observed in cases of opioid use disorder.
For veterans already grappling with addictions who initiated GLP-1 treatment, the outcomes were particularly encouraging. The study reported a 31% decrease in substance-related visits to emergency rooms, a 26% reduction in hospital admissions, a 39% drop in overdose incidents, and a 25% decline in suicidal ideation or attempts. Moreover, drug-related mortality rates fell by an impressive 50% among those on the medications.
These results align with broader trends in Maryland‘s public health landscape. Preliminary figures from the Centers for Disease Control and Prevention documented a 31% decrease in overdose deaths statewide, from 2,038 in 2024 to 1,406 in 2025. University of Maryland criminologist Peter Reuter suggested that this decline may stem from a global shortage of fentanyl precursor chemicals, disrupting supply chains and reducing availability.
The mechanism behind the drugs’ effectiveness remains under investigation, but experts believe GLP-1 drugs interact with brain reward pathways akin to those activated by food intake and addictive substances. These medications emulate a hormone produced in the intestines, enhancing insulin production and signaling satiety to the brain. Preliminary investigations have also noted that users of GLP-1 drugs tend to consume less alcohol and report diminished sensations of intoxication.
Lead author and clinical epidemiologist Ziyad Al-Aly expressed astonishment at the uniformity of the benefits across different substances. ‘I was like, ‘Is this real?’ because there is nothing like it,’ Al-Aly told Scientific American. ‘This is an obesity and diabetes drug; this is not an addiction drug. So the big surprise was: It was consistently working across all substances.’
The National Institutes of Health describes addiction as a condition that commandeers the brain’s pleasure and reward circuits, fostering intense cravings, while simultaneously heightening emotional danger-sensing mechanisms, resulting in anxiety and stress during abstinence periods.
As health care providers in Maryland continue to address the opioid crisis and other forms of substance abuse, this study offers a novel perspective on leveraging existing medications for broader therapeutic applications. One key statistical data point from the research underscores a 50% reduction in drug-related deaths, exemplified by the lower incidence of overdoses among treated veterans, potentially paving the way for integrated treatment strategies in the state’s medical facilities. For more information, visit The Baltimore Sun.